Medical devices — US PTAB Patent Cases
376 decisions indexed
Page 4 of 13 · 376 total
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products petitions the PTAB to invalidate 18 claims of Solmetex’s 2023 intraoral mesh patent, asserting anticipation and obviousness over five earlier dental mouthpiece references. The petition seeks institution of an IPR and cancellation of the challenged claims.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has filed an IPR petition challenging ten claims of Solmetex’s intraoral device patent, alleging obviousness over multiple prior‑art references. The petition seeks cancellation of claims 12‑21 and argues that the patent owner broadened claim scope after product launch.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has filed a post‑grant review petition seeking cancellation of all 31 claims of Solmetex’s dental mouthpiece patent, alleging obviousness, lack of written description, and indefiniteness. The petition leans on three earlier patents and expert testimony to argue the claims are unpatentable.
Solventum Corporation v.Wound Healing Technologies Corp.
Solventum Corp. has filed an IPR petition seeking to invalidate all 13 claims of Wound Healing Technologies' wound‑dressing patent. The petition argues the claims are obvious over prior‑art references such as Argenta, Hu, Biggie and Lockwood.
Solventum Corporation v.Wound Healing Technologies Corp.
The PTAB granted institution for IPR2025-01042, allowing Solventum Corporation to challenge Wound Healing Technologies Corp.'s patent 10639404 after finding a reasonable likelihood of prevailing.
Shenzhen Root Technology Co., Ltd. et al. v.Willow Blossom Holdco Limited et al.
Shenzhen Root Technology Co., Ltd. successfully had its Inter Partes Review petition instituted against Willow Blossom Holdco Limited for infringing on breast pump system patents. The Board found sufficient evidence to proceed with the obviousness claims, allowing the case to move forward to trial.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products has petitioned the PTAB to review U.S. Patent 11,589,969, asserting that its claims are anticipated or obvious over earlier dental mouthpiece patents. The petition outlines five statutory grounds under §§102(b) and 103, targeting claims 1‑4 and 6‑19 for cancellation.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis valve patent are unpatentable, finding anticipation and obviousness over Schaffer and combinations with Hartley, Eller, and Garrison.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. The review will cover claims 1‑9 and is based on anticipation and obviousness grounds over Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care secured institution of an IPR against Inari Medical’s hemostasis‑valve patent covering claims 1‑9. The Board found a reasonable likelihood of unpatentability based on anticipation and obviousness over Schaffer and related references.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
Ascentcare Dental Products petitions the PTAB to invalidate Solmetex’s 2025 intraoral device patent, alleging obviousness over six prior‑art references covering dental isolation mouthpieces.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care's petition to institute an IPR against Inari Medical's embolism‑treatment patent, finding no reasonable likelihood of success on any of the 31 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB institution decision in this IPR found that the petitioner met its burden of showing a reasonable likelihood of prevailing on at least claim 1. The dispute centers on obviousness (35 U.S.C. § 103) regarding medical devices used for aspirating clot material from blood vessels.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
In an IPR, the PTAB held that all nine claims of Inari Medical’s hemostasis valve patent are unpatentable under §§102 and 103, finding the petitioner’s anticipation and obviousness arguments persuasive.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care’s petition to review Inari Medical’s 11,744,691 patent covering catheter‑based embolism removal. The Board found the petitioner had not shown a reasonable likelihood of prevailing on any of the 31 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care secured institution of an IPR against Inari Medical’s hemostasis‑valve patent, covering claims 1‑9, on grounds of anticipation and obviousness.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,011 hemostasis valve patent after Imperative Care demonstrated a reasonable likelihood of unpatentability on claims 1‑9.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 patent covering a vacuum aspiration system with hemostasis valve. Petitioner Imperative Care showed a reasonable likelihood of prevailing on at least one claim, especially claim 1, based on obviousness over Garrison, Schaffer and other references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care seeks an IPR of Inari Medical’s ’333 patent covering aspiration systems for pulmonary embolism and DVT, alleging obviousness over multiple prior‑art references. The petition requests the Board to institute review of 36 claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care successfully met the institution burden in its IPR against Inari Medical's '333 patent, establishing a reasonable likelihood of prevailing on key claims. The Board found that combining prior art references like Laub and Garrison renders the claimed thromboembolism treatment systems obvious under 103.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple, on behalf of Samsung, has filed an IPR petition challenging Omni MedSci’s ’533 wearable health‑monitoring patent. The petition asserts that the claims are obvious over prior‑art references Lisogurski, Carlson, and Mannheimer and requests that the Board institute the review.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple has filed an IPR petition seeking to invalidate Omni MedSci’s ’484 wearable health‑monitoring patent. The petition asserts that the claims are obvious over a suite of prior‑art references covering optical sensing, AI processing and cloud connectivity. Apple requests that the Board institute the trial and find all claims unpatentable.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR petition challenges Omni MedSci’s ’484 wearable health‑monitoring patent, asserting that all 23 claims are obvious over a combination of prior‑art references. The petition seeks institution and a finding of unpatentability.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Samsung and Apple have filed an IPR petition challenging Omni MedSci’s ’533 patent covering wearable optical health monitors. The petition asserts obviousness over Lisogurski, Carlson, and Mannheimer references and asks the Board to institute the review and cancel the claims.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB held that Apple’s wearable physiological measurement claims were obvious over prior‑art pulse‑oximetry references, rendering all challenged claims unpatentable. The decision relied on Lisogurski, Carlson, and Mannheimer teachings.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB issued a Final Written Decision in IPR2021‑00453, finding claims 1,2,7 and 15‑23 of Omni MedSci’s wearable pulse‑oximeter patent unpatentable over prior art, while leaving the remaining claims intact.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) secured a Final Written Decision finding claims 1,2,7,15‑23 of Omni MedSci’s wearable health‑monitoring patent unpatentable as obvious over prior‑art. The Board affirmed the petitioner's obviousness arguments while leaving claims 3‑6 and 8‑14 intact.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB issued a Final Written Decision on remand, holding that all 23 claims of Omni MedSci’s wearable pulse‑oximeter patent are unpatentable. The Board relied on an obviousness analysis over a combination of prior‑art references and affirmed the claim construction of “identify an object.”
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB held that Samsung’s challenge to Omni MedSci’s wearable physiological monitoring patent succeeded on 12 of the 23 claims, finding them obvious over prior‑art references such as Lisogurski, Carlson, Tran, Isaacson and Valencell‑093. The remaining claims were not shown unpatentable.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s ‘533 patent resulted in all challenged claims being found unpatentable. The Board held that the claims were obvious over prior‑art references Lisogurski, Carlson, and Mannheimer.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.